CytomX Therapeutics, Inc. (CTMX) Income Statement
CTMX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCTMX revenue and net income
Where CTMX's revenue goes
2025Each bar shows an amount and its share of revenue. CTMX kept −22.8% of revenue as net income.
CTMX profit margins
CTMX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −44.8% | +12.8% | +2.2% | +25.7% |
| Gross profit | −44.8% | +12.8% | +2.2% | +25.7% |
| Operating income | −189.5% | — | — | — |
| Net income | −154.5% | — | — | — |
| EPS (diluted) | −110.3% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CTMX quarterly EPS vs estimates
CytomX Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.09).
CTMX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $69.6M | $68.4M | $57.5M | $59.5M | $71.6M | $15.0M |
| Cost of revenue | $0 | $1.8M | $2.2M | $5.9M | $5.8M | $0 | $0 | $0 | $105.5M | $72.9M |
| Gross profit | $76.2M | $138.1M | $101.2M | $53.2M | $69.6M | $68.4M | $57.5M | $59.5M | $71.6M | $15.0M |
| Research & development | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M | $92.3M | $54.8M |
| Sales, general & admin | $29.8M | $29.7M | $30.2M | $42.8M | $39.2M | $36.0M | $36.8M | $33.5M | $25.6M | $19.9M |
| Total operating expenses | $98.6M | $113.1M | $107.7M | $154.5M | $153.4M | $149.0M | $168.4M | $137.4M | $117.9M | $74.6M |
| Operating income | −$22.4M | $25.0M | −$6.5M | −$101.3M | −$83.8M | −$80.5M | −$110.9M | −$77.9M | −$46.3M | −$59.6M |
| Interest income | $5.2M | $7.1M | $8.1M | $1.7M | $255,000 | $1.8M | $8.4M | $7.6M | $2.7M | $2.4M |
| Interest expense | — | — | — | $2.0M | $172,000 | $1.8M | $10.8M | $0 | $0 | $1.7M |
| Income before taxes | −$17.1M | $32.1M | $3.3M | −$99.3M | −$83.6M | −$50.9M | −$102.7M | −$70.3M | −$43.6M | −$58.9M |
| Income taxes | $238,000 | $224,000 | $3.9M | −$2.0M | −$3.0M | $13.9M | −$427,000 | $14.3M | −$513,000 | −$19,000 |
| Net income | −$17.4M | $31.9M | −$569,000 | −$97.3M | −$80.6M | −$64.8M | −$102.2M | −$84.6M | −$43.1M | −$58.9M |
| EBITDA | −$15.8M | $33.9M | $5.5M | −$98.9M | −$81.1M | −$78.0M | −$108.3M | −$76.0M | −$42.0M | −$57.9M |
| EPS (diluted) | −$0.04 | $0.39 | −$0.02 | −$1.52 | −$1.31 | −$0.72 | −$2.25 | −$2.00 | −$1.17 | −$1.62 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −29.3% | 18.1% | −6.4% | −190.6% | −120.4% | −117.7% | −192.9% | −130.9% | −64.6% | −396.1% |
| Net margin | −22.8% | 23.1% | −0.6% | −183.0% | −115.9% | −94.7% | −177.8% | −142.2% | −60.2% | −391.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $663,000 | $6.0M | $18.7M | $50.9M | $38.1M | $33.4M | $25.1M | $41.5M | $26.6M | $26.4M |
| Cost of revenue | $0 | $251,000 | $510,000 | $0 | $347,000 | $0 | $413,000 | $0 | $459,000 | $467,000 | $486,000 | $1.4M |
| Gross profit | $1.4M | $10.0M | $663,000 | $6.0M | $18.7M | $50.9M | $38.1M | $33.4M | $25.1M | $41.5M | $26.6M | $25.0M |
| Research & development | $17.6M | $19.2M | $21.2M | $15.3M | $13.3M | $18.9M | $14.8M | $21.4M | $25.2M | $22.1M | $19.4M | $10.4M |
| Sales, general & admin | $7.6M | $10.7M | $7.4M | $6.4M | $6.6M | $9.4M | $5.6M | $8.0M | $8.4M | $7.8M | $7.9M | $6.8M |
| Total operating expenses | $25.2M | $29.7M | $28.6M | $21.7M | $19.9M | $28.3M | $20.4M | $29.3M | $33.6M | $29.8M | $27.2M | $13.9M |
| Operating income | −$23.8M | −$19.7M | −$27.9M | −$15.8M | −$1.3M | $22.6M | $17.7M | $4.1M | −$8.5M | $11.7M | −$606,000 | $11.1M |
| Interest income | $3.2M | $1.5M | $1.5M | $1.6M | $1.2M | $955,000 | $1.3M | $1.7M | $2.0M | $2.2M | $2.5M | $2.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.3M | — |
| Income before taxes | −$20.6M | −$18.2M | −$26.5M | −$14.2M | −$91,000 | $23.6M | $18.9M | $5.8M | −$6.5M | $13.8M | $1.9M | $5.8M |
| Income taxes | $60,000 | $59,000 | $54,000 | $58,000 | $63,000 | $62,000 | $62,000 | $61,000 | $51,000 | $49,000 | $1.1M | $2.8M |
| Net income | −$20.7M | −$18.2M | −$26.5M | −$14.2M | −$154,000 | $23.5M | $18.9M | $5.7M | −$6.5M | $13.8M | $837,000 | $3.0M |
| EBITDA | −$20.6M | −$17.9M | −$25.9M | −$14.0M | $256,000 | $24.0M | $19.4M | $6.2M | −$6.0M | $14.3M | $2.4M | $6.3M |
| EPS (diluted) | −$0.09 | −$0.10 | −$0.22 | −$0.09 | −$0.00 | $0.27 | $0.23 | $0.07 | −$0.08 | $0.17 | $0.01 | $0.04 |
| Gross margin | 100.0% | 97.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.6% |
| Operating margin | −1,677.1% | −191.8% | −4,213.0% | −264.4% | −6.9% | 44.4% | 46.4% | 12.3% | −33.7% | 28.1% | −2.3% | 42.0% |
| Net margin | −1,457.4% | −177.9% | −3,998.5% | −238.6% | −0.8% | 46.2% | 49.6% | 17.2% | −26.0% | 33.3% | 3.1% | 11.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CTMX's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CTMX financial results
In fiscal year 2025 (ended December 31, 2025), CytomX Therapeutics reported revenue of $76.2 million, down 44.8% from the year before. It had a net loss of $17.4 million, a net profit margin of −22.8%. Diluted earnings per share came to −$0.04. Over five years revenue grew at an average rate of 2.2% a year.
See the CTMX stock overview for the latest quote and news, or the CTMX chart for price history and technical indicators.
CTMX income statement FAQ
What is CytomX Therapeutics's annual revenue?
CytomX Therapeutics reported total revenue of $76.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 44.8% from $138.1 million the previous year.
Is CytomX Therapeutics profitable?
No. CytomX Therapeutics reported a net loss of $17.4 million in fiscal 2025, a net profit margin of −22.8%; its operating margin was −29.3%.
What is CytomX Therapeutics's gross margin?
CytomX Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, CytomX Therapeutics kept $100 after the direct cost of its products and services.
How much does CytomX Therapeutics spend on research and development?
CytomX Therapeutics spent $68.7 million on research and development in fiscal 2025, 90.2% of revenue.
How fast is CytomX Therapeutics growing?
Revenue grew 2.2% a year on average over the last five fiscal years, from $68.4 million to $76.2 million.
What are CytomX Therapeutics's earnings per share?
CytomX Therapeutics earned $-0.04 per diluted share in fiscal 2025, compared with $0.39 a year earlier.
When will CytomX Therapeutics report its next earnings?
CytomX Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does CytomX Therapeutics's fiscal year end?
CytomX Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.